
BioSpectrum
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

Dr. Lal PathLabs first to launch advanced test for amyloidosis

15 April 2025 | News

First diagnostic chain in South Asia to offer the highly specialised test



Dr. Lal PathLabs Limited (DLPL), a leader in diagnostic healthcare, has introduced Amyloid Typing by Laser Capture Microdissection & Mass Spectrometry – a breakthrough test for accurately identifying different types of Amyloid proteins.

With this launch, DLPL becomes the first diagnostic chain in South Asia to offer this highly specialized test.

Amyloidosis is a disease where the abnormal or misfolded amyloid protein accumulates in various vital organs leading to loss of function or even death in some cases. More than 40 types of Amyloid proteins are discovered till date, and precise knowledge about the type of Amyloid helps doctors in choosing the correct treatment or management plan for the patient. Kidney, Heart, Lungs, Skin are the most common involved, however any organ in the body can be affected.

Dr Alok Sharma, R&D Head & Director Renal Pathology & Electron Microscopy, stated, “Accurate typing of Amyloid proteins is essential for guiding treatment decisions. This gold standard advanced test, powered by Laser Microdissection & Mass Spectrometry allows us to precisely identify amyloid subtypes, helping clinicians provide targeted care. With this launch, we are bringing global standards of Proteomics based diagnostics to patients across India.”

Dr. Lal PathLabs has launched this test, under the guidance of National Amyloidosis Centre, London (UK).